A Opened, Randomized, Multi-centered Phase II study on the efficacy and safety of CreaVax-HCC(Autologous Mature Dendritic Cells)in patients with hepatocellular carcinoma for comparing after a operation and/or non-operation therapy.

Trial Profile

A Opened, Randomized, Multi-centered Phase II study on the efficacy and safety of CreaVax-HCC(Autologous Mature Dendritic Cells)in patients with hepatocellular carcinoma for comparing after a operation and/or non-operation therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Dendritic cell vaccine-CreaGene (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors JW CreaGene
  • Most Recent Events

    • 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by Clinical Research Information Service (CriS) - Republic of Korea.
    • 31 Jul 2013 Planned end date added (30 Sep 2013) as reported by Clinical Research Information Service (CriS) - Republic of Korea.
    • 31 Jul 2013 Status changed from completed to active, no longer recruiting as reported by Clinical Research Information Service (CriS) - Republic of Korea.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top